Medicis Pharmaceutical Corp. (MRX) Reports Slightly Better-Than-Expected Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $69.78 +2.05%
EPS Growth %: +27.1%
Financial Fact:
Cost of product revenues (1): 19.6M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +27.1%
Financial Fact:
Cost of product revenues (1): 19.6M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NYSE: MRX) reported Q4 EPS of $0.56, $0.01 better than the analyst estimate of $0.55. Revenue for the quarter came in at $180.7 million versus the consensus estimate of $179.2 million.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- McDonald's shares gain as profit tops expectations despite revenue miss
- Wells Fargo starts On Holding at Overweight, sees growth reaccelerating in 2027
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
